natgillin/translations-raw huggingface dataset:
c.1202 C>G
c.1215 T>A
c.1215 T>A
c.1217 A>G
c.140 G>A nebo 141 G>A
c.140 G>A or 141 G>A
c.194 G>C (domnělé místo sestřihu)
c.194 G>C (putative splicing site )
c.194 G>T (domnělé místo
c.194 G>T (putative splicing site )
c.196 G>C
c.215 T>G
c.202 C>T
c.218 C>A
c.215 T>G
c.227 T>G
c.218 C>A
c.233 C>G
c.227 T>G
c.235 G>T
c.233 C>G
c.241 T>C
c.235 G>T
c.242 G>A
c.241 T>C
c.242 G>C
c.242 G>A
c.243 G>T
c.242 G>C
c.244 A>T
c.243 G>T
c.256 T>G
c.244 A>T
c.256 T>C
c.256 T>C
c.258 T>G
c.256 T>G
c.257 A>G
c.257 A>G
c.262 T>G
c.258 T>G
c.266 T>C
c.262 T>G
c.266 T>G
c.266 T>C
c.268 T>C
c.266 T>G
c.269 G>A
c.268 T>C
c.270 C>A
c.269 G>A
c.274 G>C
c.270 C>A
c.274 G>A
c.274 G>A
c.275 A>G
c.274 G>C
c.274 G>T
c.274 G>T
c.275 A>T
c.275 A>G
c.277 G>A
c.275 A>T
c.277 G>T
c.277 G>A
c.278 A>G
c.279 C>G
c.281 G>A
c.280T>G
c.284 G>A
c.281 G>A
c.284 G>C
c.281 G>C
c.284 G>T
c.284 G>A
c.295 C>T
c.284 G>C
c.299 G>C
c.284 G>T
c.299 G>A
c.295 C>T
c.305 C>G
c.299 G>A
c.307 G>C
c.299 G>C
c.307 G>T
c.305 C>G
c.317 T>G
c.307 G>C
c.319 C>T
c.307 G>T
c.320 A>T
c.317 T>G
c.334 C>T
c.319 C>T
c.334 C>A
c.320 A>T
c.338 T>C
c.334 C>A
c.355 C>T
c.334 C>T
c.350 T>G
c.338 T>C
c.358 C>G
c.350 T>G
c.[358 C>T; 359 T>C]
c.355 C>T
c.359 T>C
c.358 C>G
c.361 G>C
c.359 T>C
c.374 A>C
c.361 G>C
c.379 A>T
c.371 T>A
c.386 T>C
c.374 A>C
c.389 A>G
c.379 A>T
c.392 T>C
c.386 T>C
c.394 G>A
c.389 A>G
c.395 G>A
c.392 T>C
c.395 G>C
c.394 G>A
c.398T>A
c.395 G>A
c.400 T>C
c.395 G>C
c.400 T>G
c.398T>A
c.401 A>C
c.400 T>C
c.402 T>G
c.400 T>G
c.406 G>C
c.401 A>C
c.406 G>T
c.402 T>G
c.412 G>A
c.406 G>C
c.413 G>A
c.406 G>T
c.416 A>C
c.412 G>A
c.422 C>A
c.413 G>A
c.422 C>T
c.416 A>C
c.424 T>C
c.422 C>A
c.425 G>A
c.422 C>T
c.426 C>A
c.424 T>C
c.426 C>G
c.425 G>A
c.427 G>C
c.426 C>A
c.439 G>A
c.426 C>G
c.440 G>A
c.427 G>C
c.443 G>A
c.439 G>A
c.444 T>G
c.440 G>A
c.453 C>G
c.443 G>A
c.456 C>A
c.444 T>G
c.463 G>C
c.453 C>G
c.467 C>A
c.456 C>A
c.469 C>T
c.463 G>C
c.484 T>C
c.467 C>A
c.485 G>A
c.469 C>T
c.485 G>T
c.484 T>C
c.486 G>C
c.485 G>A
c.488 G>T
c.485 G>T
c.491 T>G
c.486 G>C
c.493 G>T
c.488 G>T
c.494 A>T
c.491 T>G
c.500 T>A
c.493 G>T
c.500 T>C
c.494 A>T
c.503 A>G
c.500 T>A
c.504 A>C
c.508 G>C
c.509 A>T
c.509 A>G
c.511 G>C
c.547 G>A (domnělé místo sestřihu)
c.547 G>A (putative splicing site )
c.561 G>T
c.560 T>C
c.611 G>A nebo 612G>A
c.611 G>A or 612G>A
c.62 T>C
c.62 T>G
c.62 T>G
c.71 G>A
c.734 G>A nebo 735G>A
c.734 G>A or 735G>A
c.735 T>G
c.747 C>G
c.740 C>G
c.749 A>C
c.747 C>G
c.758 T>C
c.749 A>C
c.758 T>G
c.758 T>C
c.760-762del GTT
c.758 T>G
c.769 G>C
c.760-762del GTT
c.770 C>G
c.760_762delGTT
c.C770G
c.769 G>C
c.772 G>C
c.770 C>G
c.773 G>T
c.772 G>C
c.776 C>G
c.801 G>A (domnělé místo sestřihu)
c.801 G>A (putative splicing site )
c.830 G>A
c.835 C>A
c.835 C>A
c.836 A>G
c.860 G>A nebo 861G>A
c.860 G>A or 861G>A
c.898 C>T
c.901 C>G
c.899 T>C
c.902 G>C
c.901 C>G
c.902 G>A
c.902 G>A
c.908 T>A
c.902 G>C
c.902 G>T
c.902 G>T
c.911 G>A
c.908 T>A
c.911 G>C
c.911 G>A
c.919 G>A
c.911 G>C
c.924 A>T
c.919 G>A
c.925 G>C
c.924 A>T
c.928 C>T
c.925 G>C
c.931 C>G
c.928 C>T
c.935 A>G
c.931 C>G
c.936 G>T
c.935 A>G
c.937 G>T
c.936 G>T
c.938 A>G
c.937 G>T
c.946 G>A
c.938 A>G
c.947 T>G
c.946 G>A
c.950 T>C
c.947 T>G
c.955 A>T
c.950 T>C
c.956 T>C
c.955 A>T
c.959 A>T
c.956 T>C
c.962 A>G
c.959 A>T
c.962 A>T
c.962 A>G
c.963 G>C
c.962 A>T
c.964 G>C
c.963 G>C
c.966 C>A
c.964 G>C
c.973 G>A
c.966 C>A
c.973 G>C
c.973 G>A
c.979 C>G
c.973 G>C
c.983 G>C
c.979 C>G
c.1001 G>A
c.983 G>C
c.1012 G>A
c.[358 C>T; 359 T>C]
c.371 T>A
C.A. Papaellinas Ltd
Papaellinas Ltd
c.A1073C
c.G1074T
c.A1073G
c.T1076C
c.A244T
c.T256C
c.A257G
c.T262G
c.A275G
c.G277A
c.A275T
c.G277T
c.A320T
c.T338C
c.A374C
c.A389G
c.A379T
c.T392C
c.A389G
c.G395A
c.A401C
c.G406T
c.A416C
c.T424C
c.A494T
c.A503G
c.A749C
c.T758G
c.A924T
c.C928T
c.A935G
c.G937T
c.A938G
c.T947G
c.A955T
c.A959T
c.A959T
c.A962T
c.A962G
c.G963C
c.A962T
c.G964C
c.C1028T
c.G1046C
c.C1055T
c.C1066G
c.C1066G
c.G1067A
c.C1066T
c.G1067C
c.C1084A
c.C1087T
c.C1085T
c.G1088A
c.C1087T
c.G1102A
c.C1202G
c.T1215A
c.C202T
c.C218A
c.C218A
c.C233G
c.C233G
c.T241C
c.C270A
c.G274A
c.C279G
c.G281A
c.C295T
c.C305G
c.C305G
c.T317G
c.C319T
c.C334A
c.C334A
c.C355T
c.C334T
c.T350G
c.C355T
c.T359C
c.C358G
c.G361C
c.C358T/T359C
c.T371A
c.C422A
c.G425A
c.C422T
c.C426A
c.C426A
c.G439A
c.C426G
c.G440A
c.C453G
c.C467A
c.C456A
c.C469T
c.C467A
c.G485A
c.C469T
c.G485T
c.C740G
c.A749C
c.C747G
c.T758C
c.C770G
c.G773T
c.C835A
c.A836G
c.C897G
c.T899C
c.C898T
c.C901G
c.C901G
c.G902A
c.C928T
c.A935G
c.C931G
c.G936T
c.C966A
c.G973C
c.C979G
c.G1001A
c.G1001A
c.T1016A
c.G1012A
c.C1028T
c.G1046C
c.T1061A
c.G1067A
c.A1073C
c.G1067C
c.A1073G
c.G1074T
c.G1078A
c.G1078A
c.G1079A
c.G1078T
c.G1082A
c.G1079A
c.G1082C
c.G1082A
c.C1084A
c.G1082C
c.C1085T
c.G1088A
c.G1117A
c.G1196A nebo G1197A
c.G1196A or G1197A
c.G140A nebo G141A
c.G140A or G141A
c.G194C (domnělé místo sestřihu)
c.G194C (putative splicing site )
c.G194T (domnělé místo
c.G194T (putative splicing site )
c.G196C
c.T215G
c.G235T
c.G242A
c.G242A
c.G243T
c.G242C
c.A244T
c.G243T
c.T256G
c.G269A
c.G274C
c.G274A
c.A275G
c.G274C
c.G274T
c.G274T
c.A275T
c.G281A
c.G284C
c.G281C
c.G284T
c.G284A
c.C295T
c.G284C
c.G299C
c.G284T
c.G299A
c.G299A
c.G307C
c.G299C
c.G307T
c.G307C
c.C319T
c.G307T
c.A320T
c.G361C
c.A379T
c.G394A
c.T398A
c.G395A
c.T400C
c.G395C
c.T400G
c.G406C
c.G413A
c.G406T
c.A416C
c.G412A
c.C422A
c.G413A
c.C422T
c.G425A
c.G427C
c.G427C
c.G443A
c.G439A
c.T444G
c.G440A
c.C453G
c.G443A
c.C456A
c.G463C
c.T484C
c.G485A
c.G488T
c.G485T
c.T491G
c.G486C
c.G493T
c.G488T
c.A494T
c.G493T
c.T500C
c.G508C
c.A509T
c.G547A (domnělé místo sestřihu)
c.G547A (putative splicing site )
c.G561T
c.T560C
c.G730C
c.C740G
c.G734A nebo G735A
c.G734A or G735A
c.G769C
c.G772C
c.G830A
c.C835A
c.G860A nebo G861A
c.G860A or G861A
c.G902A
c.T908A
c.G902C
c.G902T
c.G902T
c.G911A
c.G911A
c.G919A
c.G911C
c.A924T
c.G919A
c.G925C
c.G925C
c.C931G
c.G936T
c.A938G
c.G937T
c.G946A
c.G946A
c.T950C
c.G963C
c.C966A
c.G964C
c.G973A
c.G973A
c.C979G
c.G973C
c.G983C
c.G983C
c.G1012A
C.I.c) C.I.c)
(95% C.I.c)
c.T1016A
c.T1033C
c.T1033C
c.C1055T
c.T1061A
c.C1066T
c.T1076C
c.G1078T
c.T1215A
c.A1217G
c.T215G
c.T227G
c.T227G
c.G235T
c.T241C
c.G242C
c.T256C
c.T258G
c.T256G
c.A257G
c.T258G
c.T266C
c.T262G
c.T266G
c.T266C
c.T268C
c.T266G
c.G269A
c.T268C
c.C270A
c.T280G
c.G284A
c.T317G
c.C334T
c.T338C
c.C358G
c.T350G
c.C358T/T359C
c.T359C
c.A374C
c.T371A
c.T386C
c.T386C
c.G394A
c.T392C
c.G395C
c.T398A
c.A401C
c.T400C
c.T402G
c.T400G
c.G406C
c.T402G
c.G412A
c.T424C
c.C426G
c.T444G
c.G463C
c.T484C
c.G486C
c.T491G
c.T500A
c.T500A
c.A504C
c.T62C
c.T62G
c.T735G
c.C747G
c.T758C
c.760_762delGTT
c.T758G
c.G769C
c.T899C
c.G902C
c.T908A
c.G911C
c.T947G
c.A955T
c.T950C
c.T956C
c.T956C
c.A962G
c.š.:
Batch:
C/ Del Sol 5, Polígono Industrial Norte
Laboratorios LETI, S.L. unipersonal C/ Del Sol 5, Polígono Industrial Norte
C/ Del Sol, 5, Poligono Industrial Norte, Tres Cantos, 28760, Madrid ŠPANĚLSKO
C/ Del Sol, 5, Poligono Industrial Norte, Tres Cantos, 28760, Madrid
C/ Veguillas – 2 Nave 16, Ajalvir 28864 (Madrid) Španělsko
C/ Veguillas – 2 Nave 16, Ajalvir 28864 (Madrid) Spain
C/Batanes 1
C/ Batanes,
c/o Icepharma hf Sími: + 354 540 8000
Servier Laboratories c/o Icepharma hf Sími: + 354 540 8000
C0h (µg/ml)
C0h (μg/ml)
C1 inhibitor je bílkovina nezbytná k regulaci „komplementového“ a „kontaktního“ systému, což je skupina krevních bílkovin, které bojují proti infekci a způsobují zánět.
The C1 inhibitor protein is required to control the ‘complement’ and ‘contact’ systems, collections of proteins in the blood that fight against infection and cause inflammation.
C1 je nejdůležitějším inhibitorem kontaktní aktivace a reguluje kontaktní systém a vlastní koagulační kaskádu vazbou na kalikrein a faktor XIIa a jejich inaktivací.
C1 is the most important inhibitor of contact activation and regulates the contact system and the intrinsic coagulation pathway by binding to and inactivating kallikrein and factor XIIa.
C12 0,97 (0,81; 1,15)
C12 0.97 (0.81, 1.15)
C12 0,99 (0,80; 1,22)
C12 0.99 (0.80, 1.22)
C12 1,00 (0,85; 1,18)
C12 1.00 (0.85, 1.18)
C12 1,00 (0,92; 1,08)
C12 1.00 (0.92, 1.08)
C12 1,07 (0,97; 1,18)
C12 1.07 (0.97, 1.18)
C12 1,47 (1,09; 2,00)
C12 1.47 (1.09, 2.00)
C12 1,70 (1,49; 1,94)
C12 1.70 (1.49, 1.94)
C12 hod raltegraviru se zvyšuje úměrně dávce v rozmezí dávek 100 mg až 800 mg a zvyšuje nepatrně méně než je úměrné dávce v rozmezí dávek 100 mg až 1 600 mg.
Raltegravir C12 hr increases dose proportionally over the dose range of 100 to 800 mg and increases slightly less than dose proportionally over the dose range 100 mg to 1,600 mg.
C12h: ↑ 3 %
C12h: ↑ 3
C12h: ↓ 13 %
C12h: ↓ 13
C12h: ↓ 21 %
C12h: ↓ 21
C12hod (nM)
C12hr (nM)
C12hod etravirinu  17 %
etravirine C12hr  17
C12hod maraviroku  10 %
maraviroc C12hr  10
C12hod raltegraviru ↑ 24 %
raltegravir C12 hr ↑ 24
C12hod raltegraviru ↑ 6 %
raltegravir C12 hr ↑ 6
C12hod raltegraviru  57 %
raltegravir C12 hr  57
C142R
C142W
C142W
G147E
C142X
G147R
C142Y
A143P
C216, HPC2002, HPC3007 a HPC3011) nebo po skutečně dokončené léčbě (studie HPC2014, HPC3017, HPC3018 a HPC3021) (LLOQ 25 IU/ml a limit detekovatelnosti 15 IU/ml, mimo u studií HPC2014 a HPC3021, kde LLOQ a limit detekovatelnosti byly 15 IU/ml).
HPC3018 and HPC3021) (LLOQ of 25 IU/ml and limit of detection of 15 IU/ml, except in studies HPC2014 and HPC3021 where LLOQ and limit of detection were 15 IU/ml).
C24 0,10 (0,07; 0,13)
C24 0.10 (0.07, 0.13)
C24 0,21 (0,17; 0,26)
C24 0.21 (0.17, 0.26)
C24 0,31 (0,25; 0,38)
C24 0.31 (0.25, 0.38)
C24 0,41 (0,28; 0,59)
C24 0.41 (0.28, 0.59)
C24 0,69 (0,54; 0,88)
Cmax 1.03 (0.96, 1.11)
C24 0,80 (0,70; 0,91)
Cmax 4.25 (3.25, 5.56)
C24 0,86 (0,79; 0,93)
C24 0.86 (0.79, 0.93)
C24 0,87 (0,70; 1,09)
C24 0.84 (0.71, 0.99)
C24 0,89 (0,78; 1,01)
C24 0.89 (0.78, 1.01)
C24 0,90 (0,82; 0,99)
C24 0.90 (0.82, 0.99)
C24 0,91 (0,82; 1,01)
C24 0.91 (0.82, 1.01)
C24 0,91 (0,87; 0,96)
C24 0.91 (0.87, 0.96)
C24 0,92 (0,18; 1,05)
C24 0.92 (0.18, 1.05)
C24 0,93 (0,84; 1,03)
C24 0.93 (0.84, 1.03)
C24 0,93 (0,87; 1,00)
C24 0.93 (0.87, 1.00)
C24 0,93 (0,88; 0,98)
C24 0.93 (0.88, 0.98)
C24 0,94 (0,87; 1,02)
C24 0.94 (0.87, 1.02)
C24 0,95 (0,87; 1,04)
C24 0.95 (0.87, 1.04)
C24 0,96 (0,86; 1,08)
C24 0.96 (0.86, 1.08)
C24 0,97 (0,89; 1,06)
C24 0.97 (0.89, 1.06)
C24 0,97 (0,92; 1,02)
C24 0.97 (0.92, 1.02)
C24 0,98 (0,88v 1,09)
C24 0.69 (0.54, 0.88)
C24 1,00 (0,93; 1,07)
C24 1.00 (0.93, 1.07)
C24 1,03 (0,91; 1,17)
C24 1.03 (0.91, 1.17)
C24 1,03 (0,92; 1,17)
Cmax 1.02 (0.92, 1.14)
C24 1,04 (0,98; 1,11)
C24 1.04 (0.98, 1.11)
C24 1,07 (0,99; 1,16)
C24 1.07 (0.99, 1.16)
C24 1,11 (1,00; 1,23)
C24 1.11 (1.00, 1.23)
C24 1,12 (0,97; 1,30)
C24 1.12 (0.97, 1.30)
C24 1,14 (0,95; 1,36)
C24 1.14 (0.95, 1.36)
C24 1,15 (1,02; 1,29)
C24 1.15 (1.02, 1.29)
C24 1,16 (1,09; 1,23)
C24 1.16 (1.09, 1.23)
C24 1,17 (1,02; 1,34)
C24 1.17 (1.02, 1.34)
C24 1,19 (1,13; 1,25)
C24 1.19 (1.13, 1.25)
C24 1,19 (1,13v 1,25)
C24 1.19 (1.13, 1.25)
C24 1,20 (1,15; 1,26)
C24 1.20 (1.15, 1.26)
C24 1,21 (1,03; 1,43)
C24 1.21 (1.03, 1.43)
C24 1,23 (1,09; 1,40)
Elbasvir
C24 1,24 (1,10; 1,39)
C24 1.24 (1.10, 1.39)
C24 1,29 (1,18; 1,41)
C24 1.29 (1.18, 1.41)
C24 1,31 (1,11; 1,55)
C24 1.31 (1.11, 1.55)
C24 1,31 (1,12; 1,53)
C24 1.31 (1.12, 1.53)
C24 1,39 (1,25; 1,56)
C24 1.39 (1.25, 1.56)
C24 1,53 (1,43; 1,63)
C24 1.53 (1.43, 1.63)
C24 1,77 (1,40; 2,24)
C24 1.77 (1.40, 2.24)
C24 1,82 (1,39; 2,39)
C24 1.82 (1.39, 2.39)
C24 1,89 (1,37; 2,60)
C24 1.89 (1.37, 2.60)
C24 11,64 (7,96; 17,02)
C24 11.64 (7.96, 17.02)
C24 2,38 (2,19; 2,60)
C24 2.38 (2.19, 2.60)
C24 21,70 (12,99; 36,25)
C24 21.70 (12.99, 36.25)
C24 3,39 (2,82; 4,09)
C24 3.39 (2.82, 4.09)
C24 4,58 (3,72; 5,64)
C24 4.58 (3.72, 5.64)
C24 8,05 (6,33; 10,24)
C24 8.05 (6.33, 10.24)
C24  32 % (Komplexní vazba na vícemocné ionty)
C24  32% (Complex binding to polyvalent ions)
C24  39 % (Komplexní vazba na vícemocné ionty)
C24  39% (Complex binding to polyvalent ions)
C24  56 % (Komplexní vazba na vícemocné ionty)
C24  56% (Complex binding to polyvalent ions)
C24hr tenofoviru  13 %
tenofovir C24hr  13
C8hr bocepreviru  26 %
boceprevir C8hr  26
C90R
C90X
C90X
D92N
C90Y
D92H
C94G
W95X
C94S
W95L
C94Y
W95S
c: 3 ráno, 3 večer d: 3 ráno, 4 večer
c: 3 morning, 3 evening d: 3 morning, 4 evening
C: pozorováno jako méně časté u prevence aterotrombotických příhod u pacientů po akutním koronárním syndromu (po perkutánní koronární intervenci)
C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)
C: pozorováno méně často u prevence aterotrombotických příhod u pacientů po akutním koronárním syndromu (po perkutánní koronární intervenci)
C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)
C: Smíchání doporučeného množství sáčků přípravku REYATAZ perorální prášek s jídlem jako je jablečná přesnídávka či jogurt v malé nádobě:
C: To mix the recommended number of REYATAZ oral powder sachets with food such as applesauce or yogurt in a small container:
c: subjekty <75 kg byly léčeny peginterferonem alfa-2b v dávce100 µg/týden a subjekty ≥75 kg dávkou peginterferonu alfa-2b 150 µg/týden. d: dávkování ribavirinu bylo 800 mg pro pacienty <60 kg, 1 000 mg pro pacienty 60-75 kg a 1 200 mg pro pacienty >75 kg.
c: subjects < 75 kg received 100 μg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 μg/week peginterferon alfa-2b. d: Ribavirin dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients > 75 kg.
c: subjekty <75 kg byly léčeny peginterferonem alfa-2b v dávce100 μg/týden a subjekty ≥75 kg dávkou peginterferonu alfa-2b 150 μg/týden. d: dávkování ribavirinu bylo 800 mg pro pacienty <60 kg, 1000 mg pro pacienty 60-75 kg a 1200 mg pro pacienty >75 kg.
c: subjects < 75 kg received 100 µg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 µg/week peginterferon alfa-2b . d: Ribavirin dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients > 75 kg.
c: subjekty s tělesnou hmotností < 75 kg dostávaly pegylovaný interferon alfa-2b v dávce 100 µg/týden a subjekty s tělesnou hmotností ≥ 75 kg dostávaly pegylovaný interferon alfa-2b v dávce 150 µg/týden. d: dávkování ribavirinu bylo 800 mg u pacientů s tělesnou hmotností < 60 kg, 1 000 mg u pacientů s tělesnou hmotností 60 - 75 kg a 1 200 mg u pacientů s tělesnou hmotností > 75 kg.
c: subjects < 75 kg received 100 µg/week pegylated interferon alfa-2b and subjects ≥ 75 kg received 150 µg/week pegylated interferon alfa-2b. d: ribavirin dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients > 75 kg.
CA 9.-52. týden
CA Wk 9-52
CA 9.–12. týden
CA* wk 9-12
CA 9–12 n/N (%)
CA 9-12 n/N (%)
CA 9–24 n/N (%)
CA 9-24 n/N (%)
CA* 13.-24. týden
CA* wk 13-24
CA* 13.-52.
70.6
CA* 15.–24. týden
CA* wk 15-24
CA* 9.–12. týden
CA* wk 9-12
Ca-DTPA (pentetan vápenatý) nebo Ca-EDTA (edetan vápenato disodný)
Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Ca-DTPA (Trinatrium - calcium pentetát) nebo
Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or
Ca-DTPA (trinatrium-kalcium-pentetát) nebo
Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or
Ca-EDTA (dinatrium-kalcium-edetát).
Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Ca-EDTA (Natrium - calcium edetát)
Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Ca-EDTA (natrium-kalcium-edetát)
Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
CA225025: Tato randomizovaná klinická studie s pacienty s metastazujícím kolorektálním karcinomem, kteří byli předtím pro metastatické onemocnění léčeni oxaliplatinou, irinotekanem a fluoropyrimidinem, srovnávala přidání cetuximabu jako samostatné látky k nejlepší podpůrné léčbě (BSC, Best Suportive Care) (287 pacientů) s nejlepší podpůrnou léčbou (285 pacientů).
CA225025: This randomised study in patients with metastatic colorectal cancer who had received prior oxaliplatin-, irinotecan- and fluoropyrimidine-based treatment for metastatic disease compared the addition of cetuximab as a single agent to best supportive care (BSC) (287 patients) with best supportive care (285 patients).
CABG: koronární arteriální bypass; GUSTO: (Globální využití strategií k otevření okludovaných koronárních arterií [Global Use of Strategies to Open Coronary Arteries]) a V analýze poolovaných studií CHAMPION bylo mírné krvácení podle škály GUSTO definováno jako jiné krvácení, které nevyžaduje transfuzi krve nebo nezpůsobuje hemodynamický kompromis. b Ve studii CHAMPION PHOENIX bylo mírné krvácení podle škály GUSTO definováno jako jiné krvácení, které vyžaduje intervenci nebo transfuzi krve nebo způsobuje hemodynamický kompromis.
CABG: Coronary Artery Bypass Graft Surgery; GUSTO: Global Use of Strategies to Open Coronary Arteries; w/o: without a In the CHAMPION pooled analysis, GUSTO Mild was defined as other bleed not requiring blood transfusion or causing haemodynamic compromise b In CHAMPION PHOENIX, GUSTO Mild was defined as other bleeding requiring intervention but not requiring blood transfusion or causing haemodynamic compromise
CABOMETYX 20 mg potahované tablety cabozantinibum
CABOMETYX 20 mg film-coated tablets cabozantinib
Cabometyx 20 mg potahované tablety EU/1/16/1136/001
Cabometyx 20 mg film-coated tablets EU/1/16/1136/001 EU/1/16/1136/002
CABOMETYX 20 mg potahované tablety jsou žluté, kulaté bez půlicí rýhy a s označením XL na jedné straně a číslicí 20 na straně druhé.
CABOMETYX 20 mg film-coated tablets are yellow, round with no score, and identified with “XL” on one side and “20” on the other side.
CABOMETYX 40 mg potahované tablety
CABOMETYX 40 mg film-coated tablets
CABOMETYX 40 mg potahované tablety cabozantinibum
CABOMETYX 40 mg film-coated tablets cabozantinib
CABOMETYX 60 mg potahované tablety
CABOMETYX 60 mg film-coated tablets
CABOMETYX 60 mg potahované tablety cabozantinibum
CABOMETYX 60 mg film-coated tablets cabozantinib
Cabometyx 60 mg potahované tablety EU/1/16/1136/005
Cabometyx 60 mg film-coated tablets EU/1/16/1136/005
CABOMETYX je indikován k léčbě pokročilého karcinomu ledvin (RCC) u dospělých, kteří už absolvovali terapii cílenou na vaskulární endoteliální růstový faktor (VEGF).
CABOMETYX is indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy
CABOMETYX je lék k léčbě rakoviny obsahující léčivou látku kabozantinib.
CABOMETYX is a cancer medicine that contains the active substance cabozantinib.
Cabometyx je protinádorový léčivý přípravek, který se používá k léčbě dospělých s pokročilým renálním karcinomem (typ rakoviny ledvin) léčených v minulosti typem protinádorového léčivého přípravku zvaného „inhibitor vaskulárního endoteliálního růstového faktoru (VEGF)“.
Cabometyx is a cancer medicine used to treat adults with advanced renal cell carcinoma (a type of kidney cancer) who have been previously treated with a type of cancer medicine called a ‘vascular endothelial growth factor (VEGF) inhibitor’.
CABOMETYX je určen k perorálnímu podání.
CABOMETYX is for oral use.
Cabometyx obsahuje léčivou látku kabozantinib.
Cabometyx contains the active substance cabozantinib.
Caelyx 2 mg/ml koncentrát pro přípravu infuzního roztoku
Caelyx 2 mg/ml concentrate for solution for infusion
Caelyx 2 mg/ml koncentrát pro přípravu infuzního roztoku Pegylovaný lipozomální doxorubicini hydrochloridum
Caelyx 2 mg/ml concentrate for solution for infusion Pegylated liposomal doxorubicin hydrochloride
Caelyx je indikován:
Caelyx is indicated:
Caelyx je podáván intravenózně v dávce 50 mg/m2 jednou za 4 týdny tak dlouho, dokud nemoc neprogreduje a léčba je pacientem stále tolerována.
Caelyx is administered intravenously at a dose of 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.
Caelyx koncentrát pro přípravu infuzního roztoku: lahvičky o obsahu 10 ml (20 mg) nebo 25 ml (50 mg).
Caelyx concentrate for solution for infusion: vials which provide 10 ml (20 mg) or 25 ml (50 mg).
Caelyx se podává nitrožilně v dávce 20 mg/m2 každé dva až tři týdny.
Caelyx is administered intravenously at 20 mg/m2 every two-to-three weeks.
Caelyx se podává v dávce 30 mg/m2 4. den 3-týdenního léčebného režimu bortezomibu ve formě 1 hodinu trvající infuze podané bezprostředně po infuzi s bortezomibem.
Caelyx is administered at 30 mg/m² on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion.
Calcium carbonicum: Současné podávání uhličitanu vápenatého (calcium carbonicum – jednorázová dávka 1500 mg) neovlivnilo farmakokinetiku cinakalcetu.
Calcium carbonate: Co-administration of calcium carbonate (single 1500 mg dose) did not alter the pharmacokinetics of cinacalcet.
Calea Floreasca, Primul District 141-143-RO Bucureşti
Calea Floreasca, Primul District 141-143 – RO Bucureşti
Calicivirus felis inactivatum (kmeny
Purevax RCPCh
Calicivirus felis inactivatum (kmeny FCV 431 a G1) .....................................................  2.0 ELISA U.
Inactivated feline calicivirus (FCV 431 and G1 strains) antigens ..................................  2.0 ELISA U.
Calicivirus felis inactivatum (kmeny FCV 431 a G1)................................................... ..  2.0 ELISA U.
Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens ..........................  2.0 ELISA U.
Calicivirus felis inactivatum (kmeny FCV 431 a G1).....................................................  2.0 ELISA U.
Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens ..........................  2.0 ELISA U.
Calicivirus felis inactivatum (kmeny FCV 431 a G1).....................................................  2.0 ELISA U.
Inactivated feline calicivirus (FCV 431 and G1 strains) antigens...................................  2.0 ELISA U.
Calicivirus septicemiae haemorrhagiae cuniculi inactivatum, typ 2 (RHDV2), kmen V-1037 ≥70% cELISA40
Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2), strain V-1037 ≥70% cELISA40
Calicivirus septicemiae haemorrhagiae cuniculi inactivatum, typ 2 (RHDV2),kmen V-1037
Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2),
California, 94043 Spojené státy americké
California, 94043 USA
California, 95054 Spojené státy americké
California, 95054 USA
Calle 8, N° 703 (esquina 5) Parque Industrial Pilar - (1629) Provincia de Buenos Aires Argentina
Calle 8, N° 703 (esquina 5) Parque Industrial Pilar - (1629) Provincia de Buenos Aires Argentina‌‌
Camberley Belgie
Camberley Belgium.
Cambridge, MA 02142 USA
Cambridge, MA 02142 USA‌
Camprodon, s/n « La Riba »
Camprodon, s/n "la Riba"
CANADE 3C-5 (kmen 1895)) rekombinantní DNA technologií
CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
CANADE 3C-5 (kmen 1895)) rekombinantní DNA technologií.
CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
canagliflozinum/metformini hydrochloridum
canagliflozin/metformin hydrochloride
Canakinumabum
Canakinumab
Cancer Resistance
resistance protein/ABCG2) and
CANCIDAS 50 mg prášek pro koncentrát pro infuzní roztok
CANCIDAS 50 mg powder for concentrate for solution for infusion
Cancidas 50 mg prášek pro koncentrát pro infuzní roztok caspofunginum
Cancidas 50 mg powder for concentrate for solution for infusion
CANCIDAS 70 mg prášek pro koncentrát pro infuzní roztok
CANCIDAS 70 mg powder for concentrate for solution for infusion
Cancidas 70 mg prášek pro koncentrát pro infuzní roztok caspofunginum
Cancidas 70 mg powder for concentrate for solution for infusion
Cancidas Cancidas
Cancidas
Cancidas je antimykotikum (léčivý přípravek proti mykotickým (houbovým) onemocněním) používané k léčbě těchto mykotických infekcí u dospělých a dětí: invazivní kandidóza (infekce způsobená kvasinkami rodu Candida).
Cancidas is an antifungal medicine used to treat the following fungal infections in adults and children:
Candida spp.
EUCAST Breakpoints
Candida), kdy slovo „invazivní“ znamená, že mykóza se rozšířila do tkání a cév,
Candida). ‘Invasive’ means that the fungus has spread into tissue and blood vessels;
Canigen L4 Injekční suspenze pro psy
Canigen L4 Suspension for injection for dogs
Canigen L4, injekční suspenze pro psy
Canigen L4, suspension for injection for dogs